Roger Graham Named President of Mylan Specialty

PITTSBURGH, June 24, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the appointment of Roger Graham as president of Mylan Specialty. Graham will report to Tony Mauro, president of Mylan North America.

Mylan CEO Heather Bresch commented, "Roger's deep brand pharmaceutical industry experience, entrepreneurial mind-set and goal-oriented leadership make him the ideal candidate to lead Mylan Specialty as we continue to expand this important business. We remain very excited about the growth prospects of the Specialty business and are confident that Roger will bring immediate value to our entire North American organization and help accelerate achievement of our ambitions for Mylan Specialty." 

Graham joins Mylan from Advandx, a private developer of in-vitro diagnostic tests in the infectious disease space. He was the company's chief commercial officer and developed its growth strategy for the U.S. and European markets.

Prior to that, Graham spent nearly a decade in executive-level marketing and sales positions at three brand pharmaceutical firms, Auxilium Pharmaceuticals, Adolor Corporation and Yamanouchi Pharma America, where he established, rebuilt and/or expanded U.S. commercial operations.

Earlier, Graham worked at Ortho McNeil, a division of Johnson & Johnson (J&J), where he was vice president of the company's $2 billion anti-infective, analgesia and urology franchise, and its 2,300 primary care and hospital sales and marketing associates. Graham also built Ortho McNeil's $500 million neuroscience and metabolic franchise via the launch and life cycle development of Topamax®.

Graham previously served as director of Marketing for Roche's CNS, pain and dermatology franchises. He began his career with Schering-Plough and, over nearly a decade, took on positions of increasing responsibility in the company's allergy, respiratory and oncology sales and marketing organizations.

Graham has a bachelor's degree in business administration from The University of Kansas and an MBA from Seton Hall University.

This press release includes statements that constitute "forward-looking statements," including with regard to the company's future growth and performance. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the impacts of competition; changes in economic and financial conditions of the company's business; the ability to attract and retain key personnel; uncertainties and matters beyond the control of management; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.